Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone

OBJECTIVE: Somapacitan is a long‐acting, reversible albumin‐binding growth hormone (GH) derivative in development. This study aimed to evaluate the safety and efficacy of once‐weekly somapacitan versus daily GH over 52 weeks in Japanese patients with adult growth hormone deficiency (AGHD). DESIGN: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuka, Fumio, Takahashi, Yutaka, Tahara, Shigeyuki, Ogawa, Yoshihisa, Højby Rasmussen, Michael, Takano, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689735/
https://www.ncbi.nlm.nih.gov/pubmed/32603494
http://dx.doi.org/10.1111/cen.14273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689735/
https://www.ncbi.nlm.nih.gov/pubmed/32603494
http://dx.doi.org/10.1111/cen.14273

Ejemplares similares